Exchange Traded Concepts’s TG Therapeutics TGTX Stock Holding History

Exchange Traded Concepts’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1M	Buy	30,193 +5,844	+24%	+$174K	0.01%	806
2025 Q4	$726K	Sell	24,349 -714	-3%	-$23.3K	0.01%	929
2025 Q3	$905K	Buy	+25,063	New	+$826K	0.01%	809
2023 Q4	–	Sell	-2,174	Closed	-$18.2K	–	1390
2023 Q3	$18.2K	Buy	+2,174	New	+$30.3K	﹤0.01%	1132

Other funds holding TGTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Exchange Traded Concepts's TGTX Position: Q1 2026 in Review

Exchange Traded Concepts increased its TG Therapeutics (TGTX) stake by 24% in Q1 2026, buying an estimated $174K and bringing the position to 30,193 shares worth $1M. The position accounts for 0.01% of the portfolio, ranked #806.

Exchange Traded Concepts first reported a position in TGTX in Q3 2023 and has held it in 4 quarters since. 363 funds tracked by Wall St. Rank hold TGTX as of Q1 2026.

Exchange Traded Concepts held 30,193 shares of TG Therapeutics worth $1M as of Q1 2026.
Exchange Traded Concepts bought 5,844 TG Therapeutics shares in Q1 2026, an estimated $174K.
TG Therapeutics made up 0.01% of Exchange Traded Concepts's portfolio in Q1 2026, its #806 holding.
Exchange Traded Concepts first reported a position in TG Therapeutics in Q3 2023 and has held it in 4 quarters since.
363 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2026.

Based on Exchange Traded Concepts's 13F filing for Q1 2026, filed 15 Apr 2026.